In this episode of Voice of Stroke, we explore new evidence shaping how lipid management can reduce stroke risk across both primary and secondary prevention.
This episode explores:
- Reassessing statin side effects using large-scale randomised trial data
- The role of PCSK9 inhibition (VESALIUS-CV) in reducing vascular events in high-risk patients without prior stroke
- Long-term data linking LDL, lipoprotein(a), and inflammation to stroke risk decades later
Together, these findings clarify safety concerns, expand preventive options, and highlight the importance of long-term risk prediction in stroke care.
This episode was written by Linxin Li, Editor-in-Chief of the Voice of Stroke Podcast, and Co-Editor Ahmad Nehme.
Note: Full transcript available here.
The following publications were mentioned in this podcast:
Fler avsnitt av ESO Voice of Stroke
Visa alla avsnitt av ESO Voice of StrokeESO Voice of Stroke med European Stroke Organisation finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.
